2022
Development and validation of a new scale to measure chronic suicidal ideation: The Chronic Suicidal Ideation Inventory-5 (CSI-5)
Garakani A, Buono FD, Larkin K, Polonsky M, Goldberg JF. Development and validation of a new scale to measure chronic suicidal ideation: The Chronic Suicidal Ideation Inventory-5 (CSI-5). Journal Of Psychiatric Research 2022, 150: 160-164. PMID: 35385817, DOI: 10.1016/j.jpsychires.2022.03.021.Peer-Reviewed Original ResearchConceptsChronic suicidal ideationSuicidal ideationSuicidal thoughtsMood disordersNovel self-report instrumentCronbach's alphaDepression severity scoresYale-Brown ObsessiveIndex hospitalizationInpatient cohortMcDonald's omegaPast suicide attemptsSeverity scoreActivity interferenceSuicide attemptsSuicidal thinkingCompulsive ScaleSelf-report instrumentOne-factor solutionIdeationSignificant Pearson correlationScoresCohortInternal consistencyAlpha
2020
Chronic Pain, Mood Disorders and Substance Use: Outcomes of Interdisciplinary Care in a Residential Psychiatric Hospital
Buono FD, Savage SR, Cerrito B, O’Connell J, Garakani A, Ackerman S, Cutter CJ. Chronic Pain, Mood Disorders and Substance Use: Outcomes of Interdisciplinary Care in a Residential Psychiatric Hospital. Journal Of Pain Research 2020, 13: 1515-1523. PMID: 32612379, PMCID: PMC7322115, DOI: 10.2147/jpr.s250568.Peer-Reviewed Original ResearchPain severityPsychiatric hospitalChronic Pain Coping InventoryChronic pain programRetrospective chart reviewOpioid use disorderPain Coping InventorySpecific psychiatric disordersCo-occurring disordersPsycho-behavioral therapySignificant differencesPain reliefChart reviewAnalgesic opioidsPain programChronic painPain interferenceInterdisciplinary careMedication managementMood disordersPain copingPsychiatric disordersUse disordersOpioidsPatients
2012
Clinician-rated versus self-rated screening for bipolar disorder among inpatients with mood symptoms and substance misuse.
Goldberg JF, Garakani A, Ackerman SH. Clinician-rated versus self-rated screening for bipolar disorder among inpatients with mood symptoms and substance misuse. The Journal Of Clinical Psychiatry 2012, 73: 1525-30. PMID: 23290325, DOI: 10.4088/jcp.12m07926.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAlcoholismBipolar DisorderCross-Sectional StudiesDiagnosis, Dual (Psychiatry)Diagnostic Self EvaluationFemaleHospitalizationHumansInterview, PsychologicalMaleMass ScreeningMiddle AgedObserver VariationPsychometricsReproducibility of ResultsSubstance-Related DisordersYoung AdultConceptsMood Disorder QuestionnaireBipolar disorderSubstance misusePredictive valueHigh negative predictive valuePatient-clinician concordanceLow positive predictive valueDSM-IV-TR criteriaMood disorder patientsHigh prevalence ratesCross-sectional assessmentCurrent substance misuseSubstance use disordersNegative predictive valuePositive predictive valueSubstance use symptomsPsychiatrist's reviewClinician interviewsPositive statusMood disordersPrevalence ratesMood symptomsLifetime substanceUse disordersBipolar diagnosis
2010
Potential Psychiatric Applications of Metabotropic Glutamate Receptor Agonists and Antagonists
Krystal JH, Mathew SJ, D’Souza D, Garakani A, Gunduz-Bruce H, Charney DS. Potential Psychiatric Applications of Metabotropic Glutamate Receptor Agonists and Antagonists. CNS Drugs 2010, 24: 669-693. PMID: 20658799, DOI: 10.2165/11533230-000000000-00000.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsPreliminary clinical trialsPositive allosteric modulatorsPsychiatric disordersClinical trialsAnimal modelsAllosteric modulatorsGroup II mGluR agonistGroup IMetabotropic glutamate receptor agonistAnxiety disordersPotential psychiatric applicationsGlutamate receptor agonistsMetabotropic glutamate receptorsTreatment of schizophreniaRole of glutamateForm of depressionMGluR agonistAntidepressant propertiesMGluR5 agonistReceptor agonistGlutamate receptorsMood disordersArea of schizophreniaPromising agentAgonists